Cerity Partners’s Sage Therapeutics SAGE Stock Holding History

Cerity Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-53,300	Closed	-$486K	–	2851
2025 Q2	$486K	Buy	53,300 +3,258	+7%	+$24K	﹤0.01%	1872
2025 Q1	$398K	Buy	+50,042	New	+$366K	﹤0.01%	1888

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cerity Partners's SAGE Position: Q3 2025 in Review

Cerity Partners sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 53,300 shares — an estimated $486K sold.

Cerity Partners first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $486K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Cerity Partners reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Cerity Partners sold 53,300 Sage Therapeutics shares in Q3 2025, an estimated $486K.
Cerity Partners first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
Cerity Partners's Sage Therapeutics position peaked at $486K in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Cerity Partners's 13F filing for Q3 2025, filed 22 Oct 2025.